Olympus Corp Ord (OCPNF) Q2 2026 Earnings Call

Investor webinar replay

Replay transcript excerpt

Today marks an exciting milestone, sharing with you the new Olympus strategy, one that builds on our evolution as a pure play medtech company, but also defines the next chapter with clarity and conviction. Let us begin with the world around us. Populations are aging quickly. Already, more than 40% of people are over 60. As people live longer, chronic diseases become more common, among them gastrointestinal, urological, and lung cancer. These trends are driving steady demand for endoscopy-enabled care. In value terms, the market grows at about 5% a year across the application field served by Olympus. In developed markets, Japan, Europe, the United States, and China, roughly 155 million endoscopy procedures are performed each year. Yet these regions represent only about a quarter of the world's population. As access to care rises in other markets, the total number of procedures could be nearly four times higher, around 600 million annually. What holds that potential back today are the barriers along the care pathway. Lack of clinician training and infrastructure in certain markets. Clinicians spending too much time on administrative work and documentation. Healthcare systems are under pressure. The overall cost of care keeps rising, yet in many regions, access remains limited. Overcoming these challenges will take extending endoscopy-enabled care into underserved markets, expanding it into adjacent disease areas and procedures that today rely on more invasive methods and democratizing advanced interventions such as ESD and ERCP. That's today. but now I want you to step with me into the future. A future where care looks and feels very differently for patients, clinicians, and administrators. Imagine a future where endoscopy-enabled care extends its benefits to many more...